Drugs end FTSE on a high

clock

The FTSE 100 has ended the session up 46 points, or 0.72%, to 6,462.4, as oil and drug stocks pushed the index higher.

AstraZeneca posted the biggest gains with a rise of 2.51% to £28.20, closely followed by GlaxoSmithKline which added 2.37% to £14.67, on the back of US pharmaceutical company Merck raising its quarterly and full year earnings guidance. Meanwhile BP climbed 2.31% to 576p, while Royal Dutch Shell ‘A’ shares added 2.3% to £17.37, although Imperial Tobacco Group limited gains by ending the session with a fall of 1.27% to £22.62. Kingfisher was the biggest loser with a fall of 1.46% to 270p, closely followed by Rolls-Royce Group which dropped 1.46% to 490.75p, while Experian fell 1.17% to 58...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Economics / Markets

'Discussion-worthy stuff': Chinese assets under pressure

'Discussion-worthy stuff': Chinese assets under pressure

China has an 18% share of global GDP and only a 3% MSCI ACWI weighting

Chris Justham
clock 02 April 2024 • 2 min read
Why investors 'can't outrun' slow-moving demographics

Why investors 'can't outrun' slow-moving demographics

'Demographic change is a key megatrend'

Darius McDermott
clock 07 March 2024 • 5 min read
Spring Budget 24: Ten key takeaways from Jeremy Hunt's speech

Spring Budget 24: Ten key takeaways from Jeremy Hunt's speech

British ISA, Office for Budget Responsibility, tax cuts

Valeria Martinez
clock 07 March 2024 • 4 min read